Psyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity preclinical study. The study was conducted on AME-1, the firms proprietary extract derived from the amanita muscaria mushroom.
The 14 day toxicity preclinical study has indicated that there were no treatment-related adverse effects on animals treated during the test period. More specifically, the company stated that, “there were no adverse clinical signs of toxicity and neither mortality nor morbidity observed in both genders for vehicle and test item-treated animals during the study period.” More importantly, the study indicated that no adverse event level occurred.
This is a major milestone for Psyched Wellness in the development of its Amanita muscaria-derived products which will help with promoting stress relief, relaxation, and assisting with restful sleeping. The 14-day and 90-day toxicological assessments of AME-1 will importantly form the foundation for all of our future preclinical studies.
Brian Tancowny, Scientific Advisor
With these results in hand, the company is now able to proceed with the next step of its product development, which consists of a 90 day oral toxicity test.
That study began just last week, with the preclinical program to be conducted by KGK Science, the firms contract research organization that also conducted the 14 day study. The extended study is expected to push the firm further along in its target of achieving preclinical approvals for its novel formulation.
Psyched Wellness last traded at $0.24 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
